CNS-pen. GABAA-_5 neg. allo. mod. (NAM)

Ph. II for Down syndrome (240 mg BID)

from 56k cmpd competition binding HTS

Sci. Rep., Apr. 8, 2021

Roche Innovation Center, Basel, CH

The Roche GABAA-α5 selective negative allosteric modulator (NAM), basmisanil, is a Ph. II candidate for intellectual disability in Down syndrome. GABAA receptors assemble as pentamers of subunits, and non- subunit selective…

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.